Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.34 |
| ▸ | SLC40A1 | Q9NP59 | 8/20 | 0.33 |
| ▸ | DHODH | Q02127 | 2/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | LIPC | P11150 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4118238 | 0.89 | POLB (0.39) | MAPK14SLC40A1DHODHROCK2KDM4E | |
| SCHEMBL4135557 | 0.88 | SLC40A1 (0.36) | MAPK14SLC40A1DHODH | |
| SCHEMBL4138889 | 0.88 | NPC1 (0.34) | SLC40A1DHODHROCK2KDM4EMAPK1 | |
| SCHEMBL4119019 | 0.84 | LIPG (0.33) | DHODHPTGDR2LIPCLIPGROCK2 | |
| SCHEMBL4130943 | 0.83 | MAPT (0.38) | ROCK2MAPTMAPK1GSK3B | |
| SCHEMBL4137742 | 0.83 | GSK3B (0.38) | MAPK14DHODHPTGDR2MAPTGSK3B | |
| SCHEMBL4123409 | 0.83 | DHODH (0.34) | MAPK14DHODHPTGDR2LIPCLIPG | |
| SCHEMBL3653705 | 0.81 | DHODH (0.33) | MAPK14DHODHPTGDR2LIPCLIPG | |
| SCHEMBL4118456 | 0.80 | LIPG (0.33) | MAPK14SLC40A1DHODHPTGDR2LIPC | |
| SCHEMBL3653706 | 0.79 | DHODH (0.32) | DHODHPTGDR2ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | MAPK14 1238/4885SLC40A1 2890/4885DHODH 1560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.